Home › Overweight › NCT07594093

Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of REGN20934 in Adult Participants With Overweight or Obesity

Who can join

Ages 18 to 65 · All sexes · Healthy volunteers welcome

Key Inclusion Criteria:

1. Has a Body Mass Index (BMI) 25 to 35 kg/m\^2
2. Females must be of non-childbearing potential

Key Exclusion Criteria:

1. A self-reported change of body weight \>5 kg within approximately 90 days of visit 2
2. History of type 1 or type 2 diabetes
3. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease, as defined in the protocol

Note: Other protocol defined inclusion/exclusion criteria apply

About the study

This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity.

The study is looking at:

* What side effects REGN20934 might cause * How much REGN20934 is in the blood at different times * If the body makes antibodies to REGN20934

What is being tested

• REGN20934 (drug)
• Placebo (drug)

Sponsor: Regeneron Pharmaceuticals · Participants: 90 · Started: Jun 29, 2026

Contact the study team

• Clinical Trials Administrator · Phone: 844-734-6643

Official record on ClinicalTrials.gov — NCT07594093

Locations in the U.S.

Conditions

• Overweight
• Obesity

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.